We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · December 29, 2019

Dabigatran Dual Therapy vs Warfarin Triple Therapy Post PCI in Patients With Atrial Fibrillation and Diabetes

JACC: Cardiovascular Interventions


Additional Info

JACC: Cardiovascular Interventions
Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes
JACC Cardiovasc Interv 2019 Dec 09;12(23)2346-2355, M Maeng, PG Steg, DL Bhatt, SH Hohnloser, M Nordaby, C Miede, T Kimura, GYH Lip, J Oldgren, JM Ten Berg, CP Cannon

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading